BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Steady concentration PD with the Carry Life UF system increased ultrafiltration nearly threefold and sodium removal nearly tenfold vs 2.5% dextrose CAPD, while improving glucose efficiency and supporting enhanced fluid management in PD patients4.6.2026 16:45:00 CEST | Press release
Triomed AB today announced positive results from a prospective, multicenter, randomized, crossover study evaluating steady concentration peritoneal dialysis using the Carry Life UF system in adult patients undergoing CAPD. The study demonstrated significant improvements in ultrafiltration, peritoneal sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume in relation to glucose absorption) compared with standard 2.5% dextrose CAPD in the home setting over four weeks. The study results were presented as a Focussed Oral presentation based on a late-breaking clinical trial abstract at the European Renal Association (ERA) Congress in Glasgow, United Kingdom, and simultaneously published in the Journal of the American Society of Nephrology (JASN). In this study, participants received their standard CAPD treatment during the control arm, whereas in the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced by a Carry Life UF treatment three days per week, and
The Empire State Building’s Tastes of New York Experience to Feature Eataly4.6.2026 16:44:00 CEST | Press release
Gelato, cannoli, and tiramisù available on the 86th Floor Observation Deck from June 4 through Aug. 31 The Empire State Building (ESB), the “World’s Most Famous Building,” today announced that it will feature Eataly as its latest Tastes of New York Experience, a year-round offering of pop-ups which feature unique New York City bites. From June 4 through Aug. 31, Eataly will bring its New York City spin on “la dolce vita” to the Empire State Building’s iconic Observation Deck with a curated selection of its most beloved desserts and beverages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604332533/en/ Gelato, cannoli, and tiramisù available on the 86th Floor Observation Deck from June 4 through Aug. 31 “We are excited to present Eataly’s true ‘estate Italiana’ as part of our year-round featured Tastes of New York to our visitors,” said Dan Rogoski, observatory general manager. “The Empire State Building can be seen and p
JCÖNTENTS “Zip to your destination, even with a language barrier.”4.6.2026 16:00:00 CEST | Press release
Converting a map into a QR code! Launching GOPin, the app that connects inbound tourists with taxis! So convenient, you’ll wonder why it never existed before! JCÖNTENTS releases free GOPin smartphone app on June 1! JCÖNTENTS Co., Ltd. (Kyoto Prefecture; Representative: Takamasa Yoshimitsu) released the free GOPin app for smartphones on June 1! GOPin is a completely new, multilingual navigation app that connects tourists visiting Japan with local taxi drivers through QR codes. All users have to do is select where they want to go on the map and show the QR code. The taxi driver will scan that to instantly display an accurate route in Google Maps. No more worries about entering addresses or pronunciation issues. GOPin doesn’t require any user registration and is free to use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601449250/en/ GOPin! For Visitors to Japan Say goodbye to the language barrier— just show your smartphone
Impartner Recognized as a Leader in G2 Summer 2026 Enterprise Grid® for Partner Relationship Management4.6.2026 15:00:00 CEST | Press release
Named a G2 Leader in both Partner Relationship Management and Through-Channel Marketing, reflecting strong customer satisfaction and enterprise momentum. Impartner, the world’s leading partner revenue orchestration platform, today announced it has been named a Leader in the G2 Summer 2026 Enterprise Grid® Report for Partner Relationship Management (PRM). The recognition underscores Impartner’s strong customer validation and continued momentum among enterprise organizations managing large-scale partner ecosystems and indirect sales channels. In the Summer 2026 report, Impartner earned Leader status based on strong customer satisfaction and adoption across organizations operating at scale. G2’s findings show a 4.5 out of 5-star rating from more than 500 verified reviews, with 91% of users indicating they would recommend the platform. Customers gave high marks for key capabilities, including Role-Based Permissions, Deal Management, and Content Repository, with Ease of Doing Business With
Fortegra Appoints Mark Rattner as President4.6.2026 15:00:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., today announced the appointment of Mark Rattner as President. Mr. Rattner, who previously served as Executive Vice President and Chief Underwriting Officer, Insurance, brings a decade of Fortegra leadership and long-standing relationships with reliable distribution partners to his expanded role. Drawing on disciplined underwriting expertise built over a career spanning more than three decades, Mr. Rattner is focused on delivering the highest value and consistent results to the agents and brokers the company serves. His appointment reflects Fortegra’s continued investment in the people and partnerships that drive long-term, sustainable profitability. “Mark has been central to building Fortegra into the company it is today. His industry experience, knowledge, and trade craft make him the right person for this role. As we continue to evolve, Mark will enhance our partners
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom